Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Novavax (NVAX) has drawn fresh attention after a recent ...
StockStory.org on MSN
Amphastar Pharmaceuticals, Novavax, and Organon shares skyrocket, what you need to know
What Happened? A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes ...
The biotech’s licensing pact with Pfizer, revealed last week, will leverage its adjuvant vaccine platform in the development of two undisclosed Pfizer products. After pocketing ...
Zacks Investment Research on MSN
Novavax (NVAX) rises as market takes a dip: Key facts
Novavax (NVAX) closed at $8.97 in the latest trading session, marking a +2.51% move from the prior day. The stock outperformed the S&P 500, which registered a daily loss of 0.01%. Meanwhile, the Dow ...
Ampoules of Novavax's COVID-19 vaccine prepared in Berlin, Germany. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...
Following its emergency authorization last month, just 7,300 doses of Novavax's COVID-19 vaccine have been administered to Americans across the country, newly updated data from the Centers for Disease ...
(Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no ...
Moderna, Inc. vs. Novavax, Inc.: cost cuts, vaccine pipeline catalysts, and valuations. Click for this comparison of NVAX and MRNA and see which is better for you.
WASHINGTON — The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine but with unusual restrictions. Novavax makes the nation’s only traditional protein-based ...
A medical worker prepares ampoules of the Nuvaxovid vaccine against Covid-19 by Novavax at the Tegel vaccination center on February 28, 2022 in Berlin, Germany. This story was originally published on ...
Gaithersburg-based Novavax said Tuesday it signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to vaccines for use in up to two infectious diseases, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results